Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2017
May 8, 2017 4:05 PM EDTRANCHO CUCAMONGA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended March 31, 2017.
First Quarter Highlights
Net revenues of $56.7 million for the first quarterGAAP net income of $0.9 million, or $0.02 per diluted share, for the first quarterAdjusted non-GAAP net income of $4.5 million, or $0.09 per diluted share, for the first quarterDr. Jack Zhang, Amphastars CEO, commented:Â We continue to execute on our... More
